A5101637952- Brucella: diagnosis, epidemiology, treatment
- Antibiotics Pharmacokinetics and Efficacy
- Bacterial Infections and Vaccines
- Leptospirosis research and findings
- Respiratory viral infections research
- Nosocomial Infections in ICU
- Burkholderia infections and melioidosis
- Pneumonia and Respiratory Infections
- Antibiotic Resistance in Bacteria
Baotou Central Hospital
2023-2025
Inner Mongolia Medical University
2023
Inner Mongolia University of Science and Technology
2023
Baotou Medical College
2023
Ceftazidime-avibactam was approved in patients with hospital-acquired pneumonia (HAP), including ventilator-associated (VAP), based on the multinational Phase 3 REPROVE study. This study assessed efficacy and safety of ceftazidime-avibactam Chinese adults HAP/VAP. a 4, prospective, multi-centre, open-label study, conducted at 42 sites China. Patients HAP/VAP received 2.5 g by 2-hour IV infusion every 8 hours for 7-14 days. Primary endpoint clinical response test-of-cure (TOC) visit modified...
Nemonoxacin malate is a novel non-fluorinated quinolone for oral and intravenous (IV) administration. This phase 3 multicentre, randomised, double-blind, double-dummy, parallel-controlled clinical trial (NCT02205112) evaluated the efficacy safety of IV nemonoxacin versus levofloxacin treatment community-acquired pneumonia (CAP) in adult patients. The eligible patients were randomised to receive 500 mg or via infusion, once daily 7-14 days. primary endpoint was cure rate at test (TOC) visit...
Pleurisy and pleural effusion caused by Brucella infection are rare. However, clinicians lack an understanding of these possibilities, the underlying disorder is easy to misdiagnose. We report a 52-year-old male farmer who was admitted hospital with fever, chest pain, shortness breath. Closed drainage performed thoracocentesis, concentration adenosine deaminase (ADA) in fluid >45 U/L. Mononuclear cells accounted for 90% cells, pathology indicated large number lymphocytes. The clinical...